{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034811",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034811_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"acebutolol\" outputclass=\"int-drug\">acebutolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  acebutolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acebutolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034812",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034812_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"agomelatine\" outputclass=\"int-drug\">agomelatine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  agomelatine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Agomelatine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034813",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034813_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  alcohol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034813_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alcohol\" outputclass=\"int-drug\">alcohol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  alcohol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alcohol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034814",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034814_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alfentanil\" outputclass=\"int-drug\">alfentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  alfentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034815",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034815_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alfuzosin\" outputclass=\"int-drug\">alfuzosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  alfuzosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alfuzosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034816",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034816_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alimemazine\" outputclass=\"int-drug\">alimemazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  alimemazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alimemazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034817",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034817_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  aliskiren  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034818",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034818_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alprazolam\" outputclass=\"int-drug\">alprazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  alprazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034819",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034819_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  alprostadil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034820",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034820_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amantadine\" outputclass=\"int-drug\">amantadine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  amantadine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034820_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"amantadine\" outputclass=\"int-drug\">amantadine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   amantadine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amantadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034821",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034821_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amifampridine\" outputclass=\"int-drug\">amifampridine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  amifampridine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amifampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034822",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034822_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"aminophylline\" outputclass=\"int-drug\">Aminophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Aminophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aminophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034823",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034823_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">amiodarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  amiodarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034824",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034824_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  amisulpride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034824_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amisulpride\" outputclass=\"int-drug\">amisulpride</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  amisulpride  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amisulpride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034825",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034825_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  amitriptyline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034825_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  amitriptyline  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034826",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034826_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"amlodipine\" outputclass=\"int-drug\">amlodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  amlodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amlodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034827",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034827_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"amphotericin B\" outputclass=\"int-drug\">Amphotericin B</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Amphotericin B   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin B</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034828",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034828_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  anagrelide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034829",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034829_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">apalutamide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  apalutamide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034830",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034830_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  apomorphine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034830_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  apomorphine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034830_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"apomorphine\" outputclass=\"int-drug\">apomorphine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "3",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   apomorphine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apomorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034831",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034831_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  apraclonidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034831_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"apraclonidine\" outputclass=\"int-drug\">apraclonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  apraclonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apraclonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034832",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034832_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  aripiprazole  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034832_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"aripiprazole\" outputclass=\"int-drug\">aripiprazole</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  aripiprazole  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aripiprazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034833",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034833_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  arsenic trioxide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034834",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034834_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"artemether\" outputclass=\"int-drug\">artemether</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  artemether  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artemether</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034835",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034835_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"artenimol\" outputclass=\"int-drug\">artenimol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  artenimol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Artenimol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034836",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034836_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"articaine\" outputclass=\"int-drug\">articaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  articaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Articaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034837",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034837_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  asenapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034837_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"asenapine\" outputclass=\"int-drug\">asenapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  asenapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asenapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034838",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034838_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"atenolol\" outputclass=\"int-drug\">atenolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  atenolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atenolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034839",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034839_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"avanafil\" outputclass=\"int-drug\">avanafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  avanafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Avanafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034840",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034840_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  azilsartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034841",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034841_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  baclofen  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034841_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"baclofen\" outputclass=\"int-drug\">baclofen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  baclofen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Baclofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034842",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034842_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bambuterol\" outputclass=\"int-drug\">Bambuterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bambuterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bambuterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034843",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034843_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">Beclometasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Beclometasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034844",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034844_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bedaquiline\" outputclass=\"int-drug\">bedaquiline</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bedaquiline  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bedaquiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034845",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034845_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bendroflumethiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034845_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">Bendroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bendroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034846",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034846_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  benperidol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034846_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"benperidol\" outputclass=\"int-drug\">benperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  benperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034847",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034847_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">Betamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Betamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034848",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034848_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"betaxolol\" outputclass=\"int-drug\">betaxolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  betaxolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betaxolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034849",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034849_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bisoprolol\" outputclass=\"int-drug\">bisoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bisoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bisoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034850",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034850_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bortezomib  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034851",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034851_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bosutinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034852",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034852_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  brimonidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034852_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"brimonidine\" outputclass=\"int-drug\">brimonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  brimonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brimonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034853",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034853_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bromocriptine\" outputclass=\"int-drug\">bromocriptine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bromocriptine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034853_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"bromocriptine\" outputclass=\"int-drug\">bromocriptine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   bromocriptine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromocriptine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034854",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034854_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"buclizine\" outputclass=\"int-drug\">buclizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  buclizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034855",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034855_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"budesonide\" outputclass=\"int-drug\">Budesonide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Budesonide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034856",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034856_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bumetanide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034856_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">Bumetanide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bumetanide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034857",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034857_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"bupivacaine\" outputclass=\"int-drug\">bupivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  bupivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034858",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034858_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"buprenorphine\" outputclass=\"int-drug\">buprenorphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  buprenorphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buprenorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034859",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034859_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cabergoline\" outputclass=\"int-drug\">cabergoline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cabergoline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034859_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"cabergoline\" outputclass=\"int-drug\">cabergoline</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   cabergoline .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabergoline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034860",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034860_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cabozantinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034861",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034861_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  canagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034862",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034862_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  candesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034863",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034863_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cannabidiol\" outputclass=\"int-drug\">cannabidiol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cannabidiol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cannabidiol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034864",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034864_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  captopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034865",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034865_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cariprazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034865_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cariprazine\" outputclass=\"int-drug\">cariprazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  cariprazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cariprazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034866",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034866_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"carvedilol\" outputclass=\"int-drug\">carvedilol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  carvedilol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carvedilol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034867",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034867_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"celiprolol\" outputclass=\"int-drug\">celiprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  celiprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celiprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034868",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034868_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cenobamate\" outputclass=\"int-drug\">cenobamate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cenobamate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cenobamate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034869",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034869_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ceritinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034870",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034870_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chloral hydrate\" outputclass=\"int-drug\">chloral hydrate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chloral hydrate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloral hydrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034871",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034871_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlordiazepoxide\" outputclass=\"int-drug\">chlordiazepoxide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chlordiazepoxide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlordiazepoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034872",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034872_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chloroprocaine\" outputclass=\"int-drug\">chloroprocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chloroprocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloroprocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034873",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034873_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chlorothiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034873_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">Chlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Chlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034874",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034874_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlorphenamine\" outputclass=\"int-drug\">chlorphenamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chlorphenamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorphenamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034875",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034875_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chlorpromazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034875_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  chlorpromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034875_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlorpromazine\" outputclass=\"int-drug\">chlorpromazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  chlorpromazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorpromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034876",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034876_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  chlortalidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034876_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">Chlortalidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Chlortalidone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034877",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034877_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cinnarizine\" outputclass=\"int-drug\">cinnarizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cinnarizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cinnarizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034878",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034878_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  citalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034879",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034879_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">clarithromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clarithromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034880",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034880_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clemastine\" outputclass=\"int-drug\">clemastine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clemastine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clemastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034881",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034881_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clobazam\" outputclass=\"int-drug\">clobazam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clobazam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clobazam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034882",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034882_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clomethiazole\" outputclass=\"int-drug\">clomethiazole</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clomethiazole  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomethiazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034883",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034883_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clomipramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034883_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  clomipramine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034883_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  clomipramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034884",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034884_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clonazepam\" outputclass=\"int-drug\">clonazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clonazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034885",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034885_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clonidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034885_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clonidine\" outputclass=\"int-drug\">clonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  clonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034886",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034886_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  clozapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034886_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"clozapine\" outputclass=\"int-drug\">clozapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  clozapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clozapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034887",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034887_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"codeine\" outputclass=\"int-drug\">codeine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  codeine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Codeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034888",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034888_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"crizotinib\" outputclass=\"int-drug\">crizotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  crizotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crizotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034889",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034889_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cyclizine\" outputclass=\"int-drug\">cyclizine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cyclizine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyclizine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034890",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034890_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"cyproheptadine\" outputclass=\"int-drug\">cyproheptadine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  cyproheptadine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproheptadine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034891",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034891_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dapagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034892",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034892_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dasatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034893",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034893_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">Deflazacort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Deflazacort   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034894",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034894_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"delamanid\" outputclass=\"int-drug\">delamanid</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  delamanid  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delamanid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034895",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034895_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  desflurane  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034895_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  desflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034895_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"desflurane\" outputclass=\"int-drug\">desflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  desflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034896",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034896_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">Dexamethasone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dexamethasone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034897",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034897_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dexmedetomidine\" outputclass=\"int-drug\">dexmedetomidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dexmedetomidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexmedetomidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034898",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034898_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"diamorphine\" outputclass=\"int-drug\">diamorphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  diamorphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diamorphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034899",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034899_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"diazepam\" outputclass=\"int-drug\">diazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  diazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034900",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034900_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"diazoxide\" outputclass=\"int-drug\">diazoxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  diazoxide  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diazoxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034901",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034901_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dihydrocodeine\" outputclass=\"int-drug\">dihydrocodeine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dihydrocodeine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dihydrocodeine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034902",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034902_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"diltiazem\" outputclass=\"int-drug\">diltiazem</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  diltiazem  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diltiazem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034903",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034903_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dipipanone\" outputclass=\"int-drug\">dipipanone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dipipanone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipipanone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034904",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034904_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dipyridamole  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034905",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034905_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"disopyramide\" outputclass=\"int-drug\">disopyramide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  disopyramide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Disopyramide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034906",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034906_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"domperidone\" outputclass=\"int-drug\">Domperidone</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Domperidone   increases   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Domperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034907",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034907_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dosulepin  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034907_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  dosulepin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034908",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034908_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"doxazosin\" outputclass=\"int-drug\">doxazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  doxazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034909",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034909_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  doxepin  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034909_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  doxepin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034910",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034910_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dronabinol\" outputclass=\"int-drug\">dronabinol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dronabinol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronabinol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034911",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034911_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"dronedarone\" outputclass=\"int-drug\">dronedarone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  dronedarone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dronedarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034912",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034912_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  droperidol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034912_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  droperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034912_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"droperidol\" outputclass=\"int-drug\">droperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  droperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Droperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034913",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034913_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">efavirenz</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  efavirenz  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034914",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034914_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  empagliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034915",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034915_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  enalapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034916",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034916_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">encorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  encorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034917",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034917_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"entrectinib\" outputclass=\"int-drug\">entrectinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  entrectinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Entrectinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034918",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034918_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  eplerenone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034919",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034919_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  epoprostenol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034920",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034920_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  eprosartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034921",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034921_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  eribulin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034922",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034922_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ertugliflozin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034923",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034923_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"erythromycin\" outputclass=\"int-drug\">erythromycin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  erythromycin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erythromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034924",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034924_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  escitalopram  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034925",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034925_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  esketamine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034925_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"esketamine\" outputclass=\"int-drug\">esketamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  esketamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034926",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034926_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"esmolol\" outputclass=\"int-drug\">esmolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  esmolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Esmolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034927",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034927_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  etomidate  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034927_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"etomidate\" outputclass=\"int-drug\">etomidate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  etomidate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etomidate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034928",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034928_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"felodipine\" outputclass=\"int-drug\">felodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  felodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Felodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034929",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034929_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  fentanyl  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034930",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034930_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fingolimod\" outputclass=\"int-drug\">Fingolimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fingolimod   might   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fingolimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034931",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034931_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"flecainide\" outputclass=\"int-drug\">flecainide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  flecainide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flecainide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034932",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034932_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">fluconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  fluconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034933",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034933_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">Fludrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fludrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034934",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034934_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  flupentixol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034934_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"flupentixol\" outputclass=\"int-drug\">flupentixol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  flupentixol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flupentixol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034935",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034935_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"flurazepam\" outputclass=\"int-drug\">flurazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  flurazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034936",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034936_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"formoterol\" outputclass=\"int-drug\">Formoterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Formoterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Formoterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034937",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034937_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"fosinopril\" outputclass=\"int-drug\">fosinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  fosinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034938",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034938_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  furosemide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034938_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"furosemide\" outputclass=\"int-drug\">Furosemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Furosemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034939",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034939_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  gabapentin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034940",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034940_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"glasdegib\" outputclass=\"int-drug\">glasdegib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  glasdegib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glasdegib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034941",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034941_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"glyceryl trinitrate\" outputclass=\"int-drug\">glyceryl trinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  glyceryl trinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glyceryl trinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034942",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034942_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"granisetron\" outputclass=\"int-drug\">Granisetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Granisetron   is predicted to   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034943",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034943_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  guanfacine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034943_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"guanfacine\" outputclass=\"int-drug\">guanfacine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  guanfacine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Guanfacine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034944",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034944_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  haloperidol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034944_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  haloperidol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034944_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"haloperidol\" outputclass=\"int-drug\">haloperidol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  haloperidol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Haloperidol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034945",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034945_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydralazine\" outputclass=\"int-drug\">hydralazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  hydralazine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydralazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034946",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034946_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  hydrochlorothiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034946_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">Hydrochlorothiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Hydrochlorothiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034947",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034947_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">Hydrocortisone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Hydrocortisone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034948",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034948_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  hydroflumethiazide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034948_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">Hydroflumethiazide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Hydroflumethiazide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034949",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034949_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydromorphone\" outputclass=\"int-drug\">hydromorphone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  hydromorphone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydromorphone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034950",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034950_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydroxychloroquine\" outputclass=\"int-drug\">hydroxychloroquine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  hydroxychloroquine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxychloroquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034951",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034951_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  hydroxyzine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034951_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"hydroxyzine\" outputclass=\"int-drug\">hydroxyzine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  hydroxyzine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxyzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034952",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034952_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  iloprost  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034953",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034953_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  imidapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034954",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034954_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  imipramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034954_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  imipramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034955",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034955_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indacaterol\" outputclass=\"int-drug\">Indacaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Indacaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indacaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034956",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034956_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  indapamide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034956_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"indapamide\" outputclass=\"int-drug\">Indapamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Indapamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034957",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034957_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"indoramin\" outputclass=\"int-drug\">indoramin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  indoramin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indoramin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034958",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034958_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  inotuzumab ozogamicin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034959",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034959_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  irbesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034960",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034960_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  isocarboxazid  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034961",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034961_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  isoflurane  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034961_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  isoflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034961_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"isoflurane\" outputclass=\"int-drug\">isoflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  isoflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034962",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034962_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"isosorbide dinitrate\" outputclass=\"int-drug\">isosorbide dinitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  isosorbide dinitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide dinitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034963",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034963_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"isosorbide mononitrate\" outputclass=\"int-drug\">isosorbide mononitrate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  isosorbide mononitrate  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isosorbide mononitrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034964",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034964_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ivabradine\" outputclass=\"int-drug\">Ivabradine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of torsade de pointes when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ivabradine   is predicted to   increase   the risk of torsade de pointes when given with   zuclopenthixol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ivabradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034965",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034965_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ketamine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034965_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ketamine\" outputclass=\"int-drug\">ketamine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  ketamine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034966",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034966_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ketotifen\" outputclass=\"int-drug\">ketotifen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ketotifen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034967",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034967_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"labetalol\" outputclass=\"int-drug\">labetalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  labetalol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Labetalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034968",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034968_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lacidipine\" outputclass=\"int-drug\">lacidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lacidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lacidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034969",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034969_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lamotrigine\" outputclass=\"int-drug\">lamotrigine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lamotrigine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lamotrigine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034970",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034970_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lapatinib\" outputclass=\"int-drug\">lapatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lapatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lapatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034971",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034971_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lenvatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034972",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034972_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lercanidipine\" outputclass=\"int-drug\">lercanidipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lercanidipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lercanidipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034973",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034973_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"levetiracetam\" outputclass=\"int-drug\">levetiracetam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  levetiracetam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levetiracetam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034974",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034974_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"levobunolol\" outputclass=\"int-drug\">levobunolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  levobunolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levobunolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034975",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034975_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  levodopa  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034975_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"levodopa\" outputclass=\"int-drug\">levodopa</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or monitor worsening parkinsonian symptoms</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   levodopa .  Manufacturer advises avoid or monitor worsening parkinsonian symptoms .    \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levodopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034976",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034976_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  levomepromazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034976_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  levomepromazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034976_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"levomepromazine\" outputclass=\"int-drug\">levomepromazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  levomepromazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levomepromazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034977",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034977_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lidocaine\" outputclass=\"int-drug\">lidocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lidocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lidocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034978",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034978_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lisinopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034979",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034979_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lithium  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034979_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of neurotoxicity when given with</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if neurotoxicity develops</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   potentially   increases   the risk of neurotoxicity when given with   lithium .  Manufacturer advises discontinue if neurotoxicity develops .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034980",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034980_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">lofepramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lofepramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034980_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lofepramine\" outputclass=\"int-drug\">lofepramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  lofepramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofepramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034981",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034981_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lofexidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034981_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  lofexidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034981_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lofexidine\" outputclass=\"int-drug\">lofexidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  lofexidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lofexidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034982",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034982_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"loprazolam\" outputclass=\"int-drug\">loprazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  loprazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loprazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034983",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034983_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lorazepam\" outputclass=\"int-drug\">lorazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lorazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lorazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034984",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034984_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lormetazepam\" outputclass=\"int-drug\">lormetazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lormetazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lormetazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034985",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034985_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  losartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034986",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034986_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  loxapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034986_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"loxapine\" outputclass=\"int-drug\">loxapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  loxapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Loxapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034987",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034987_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  lurasidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034987_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"lurasidone\" outputclass=\"int-drug\">lurasidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  lurasidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lurasidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034988",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034988_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mefloquine\" outputclass=\"int-drug\">Mefloquine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mefloquine   is predicted to   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefloquine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034989",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034989_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"melatonin\" outputclass=\"int-drug\">melatonin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  melatonin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Melatonin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034990",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034990_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"mepivacaine\" outputclass=\"int-drug\">mepivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  mepivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mepivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034991",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034991_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"meptazinol\" outputclass=\"int-drug\">meptazinol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  meptazinol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meptazinol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034992",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034992_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  methadone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034992_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  methadone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034993",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034993_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"methocarbamol\" outputclass=\"int-drug\">methocarbamol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  methocarbamol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methocarbamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034994",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034994_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  methoxyflurane  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034994_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"methoxyflurane\" outputclass=\"int-drug\">methoxyflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  methoxyflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxyflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034995",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034995_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"methyldopa\" outputclass=\"int-drug\">methyldopa</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  methyldopa  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methyldopa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034996",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034996_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">Methylprednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Methylprednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034997",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034997_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  metolazone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034997_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"metolazone\" outputclass=\"int-drug\">Metolazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Metolazone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034998",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034998_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"metoprolol\" outputclass=\"int-drug\">metoprolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  metoprolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metoprolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034999",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858034999_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  mianserin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035000",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035000_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"midazolam\" outputclass=\"int-drug\">midazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  midazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Midazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035001",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035001_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"minoxidil\" outputclass=\"int-drug\">minoxidil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  minoxidil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Minoxidil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035002",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035002_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  mirtazapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035003",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035003_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mizolastine\" outputclass=\"int-drug\">Mizolastine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mizolastine   is predicted to   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mizolastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035004",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035004_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"morphine\" outputclass=\"int-drug\">morphine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  morphine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Morphine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035005",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035005_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  moxifloxacin  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035006",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035006_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"moxisylyte\" outputclass=\"int-drug\">moxisylyte</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  moxisylyte  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxisylyte</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035007",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035007_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  moxonidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035007_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"moxonidine\" outputclass=\"int-drug\">moxonidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  moxonidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "197",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxonidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035008",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035008_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nabilone\" outputclass=\"int-drug\">nabilone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nabilone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "198",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabilone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035009",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035009_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nadolol\" outputclass=\"int-drug\">nadolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nadolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "199",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nadolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035010",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035010_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nebivolol\" outputclass=\"int-drug\">nebivolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nebivolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "200",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nebivolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035011",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035011_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nicardipine\" outputclass=\"int-drug\">nicardipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nicardipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "201",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicardipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035012",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035012_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">nicorandil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nicorandil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "202",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035013",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035013_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nifedipine\" outputclass=\"int-drug\">nifedipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nifedipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "203",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nifedipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035014",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035014_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nilotinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "204",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035015",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035015_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nimodipine\" outputclass=\"int-drug\">nimodipine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nimodipine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "205",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nimodipine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035016",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035016_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nitrazepam\" outputclass=\"int-drug\">nitrazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nitrazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "206",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035017",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035017_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nitroprusside\" outputclass=\"int-drug\">nitroprusside</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nitroprusside  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "207",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitroprusside</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035018",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035018_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nitrous oxide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035018_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nitrous oxide\" outputclass=\"int-drug\">nitrous oxide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  nitrous oxide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "208",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nitrous oxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035019",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035019_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  nortriptyline  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035019_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  nortriptyline  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "209",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035020",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035020_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  olanzapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035020_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"olanzapine\" outputclass=\"int-drug\">olanzapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  olanzapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "210",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olanzapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035021",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035021_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  olmesartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "211",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035022",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035022_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"olodaterol\" outputclass=\"int-drug\">Olodaterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Olodaterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "212",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olodaterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035023",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035023_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ondansetron  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "213",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035024",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035024_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"osilodrostat\" outputclass=\"int-drug\">osilodrostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  osilodrostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "214",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osilodrostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035025",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035025_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"osimertinib\" outputclass=\"int-drug\">osimertinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  osimertinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "215",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Osimertinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035026",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035026_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"oxazepam\" outputclass=\"int-drug\">oxazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  oxazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "216",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035027",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035027_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"oxycodone\" outputclass=\"int-drug\">oxycodone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  oxycodone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "217",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxycodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035028",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035028_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ozanimod\" outputclass=\"int-drug\">Ozanimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ozanimod   might   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "218",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ozanimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035029",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035029_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  paliperidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035029_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  paliperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035029_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"paliperidone\" outputclass=\"int-drug\">paliperidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  paliperidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "219",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paliperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035030",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035030_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">Palonosetron</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Palonosetron   is predicted to   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "220",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035031",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035031_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  panobinostat  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "221",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035032",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035032_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pasireotide\" outputclass=\"int-drug\">pasireotide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pasireotide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "222",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pasireotide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035033",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035033_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pazopanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "223",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035034",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035034_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Intravenous</ph> <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Intravenous   pentamidine   potentially   increases   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "224",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035035",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035035_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pentazocine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "225",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035036",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035036_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"perampanel\" outputclass=\"int-drug\">perampanel</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  perampanel  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "226",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perampanel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035037",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035037_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pericyazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035037_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pericyazine\" outputclass=\"int-drug\">pericyazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  pericyazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "227",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pericyazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035038",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035038_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  perindopril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "228",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035039",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035039_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pethidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "229",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035040",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035040_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  phenelzine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "230",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035041",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035041_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">phenobarbital</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  phenobarbital  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "231",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035042",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035042_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pimozide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035042_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  pimozide  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035042_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pimozide\" outputclass=\"int-drug\">pimozide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  pimozide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "232",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pimozide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035043",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035043_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pindolol\" outputclass=\"int-drug\">pindolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pindolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "233",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pindolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035044",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035044_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pizotifen\" outputclass=\"int-drug\">pizotifen</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pizotifen  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "234",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pizotifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035045",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035045_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ponesimod\" outputclass=\"int-drug\">Ponesimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ponesimod   might   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "235",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponesimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035046",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035046_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pramipexole  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035046_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   pramipexole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "236",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pramipexole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035047",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035047_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"prazosin\" outputclass=\"int-drug\">prazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  prazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "237",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035048",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035048_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">Prednisolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Prednisolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "238",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035049",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035049_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"pregabalin\" outputclass=\"int-drug\">pregabalin</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  pregabalin  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "239",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pregabalin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035050",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035050_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"prilocaine\" outputclass=\"int-drug\">prilocaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  prilocaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "240",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prilocaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035051",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035051_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"primidone\" outputclass=\"int-drug\">primidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  primidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "241",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035052",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035052_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  prochlorperazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035052_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"prochlorperazine\" outputclass=\"int-drug\">prochlorperazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  prochlorperazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "242",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prochlorperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035053",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035053_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  promazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035053_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"promazine\" outputclass=\"int-drug\">promazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  promazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "243",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035054",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035054_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"promethazine\" outputclass=\"int-drug\">promethazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  promethazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "244",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Promethazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035055",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035055_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  propofol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035055_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"propofol\" outputclass=\"int-drug\">propofol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  propofol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "245",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propofol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035056",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035056_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"propranolol\" outputclass=\"int-drug\">propranolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  propranolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "246",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Propranolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035057",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035057_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  quetiapine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035057_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"quetiapine\" outputclass=\"int-drug\">quetiapine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  quetiapine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "247",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quetiapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035058",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035058_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"quinagolide\" outputclass=\"int-drug\">quinagolide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  quinagolide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035058_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"quinagolide\" outputclass=\"int-drug\">quinagolide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   quinagolide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "248",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinagolide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035059",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035059_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  quinapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "249",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035060",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035060_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"quinine\" outputclass=\"int-drug\">quinine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  quinine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "250",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035061",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035061_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ramipril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "251",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035062",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035062_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ranolazine\" outputclass=\"int-drug\">ranolazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ranolazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "252",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranolazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035063",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035063_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"remifentanil\" outputclass=\"int-drug\">remifentanil</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  remifentanil  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "253",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Remifentanil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035064",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035064_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"remimazolam\" outputclass=\"int-drug\">remimazolam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  remimazolam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "254",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Remimazolam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035065",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035065_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ribociclib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "255",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035066",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035066_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"riociguat\" outputclass=\"int-drug\">riociguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  riociguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "256",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Riociguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035067",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035067_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  risperidone  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035067_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  risperidone  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035067_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"risperidone\" outputclass=\"int-drug\">risperidone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  risperidone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "257",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Risperidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035068",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035068_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ropinirole\" outputclass=\"int-drug\">ropinirole</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ropinirole  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035068_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"ropinirole\" outputclass=\"int-drug\">ropinirole</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   ropinirole .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "258",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropinirole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035069",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035069_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"ropivacaine\" outputclass=\"int-drug\">ropivacaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  ropivacaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "259",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropivacaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035070",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035070_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"rotigotine\" outputclass=\"int-drug\">rotigotine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  rotigotine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035070_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">Zuclopenthixol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"rotigotine\" outputclass=\"int-drug\">rotigotine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "2",
							"hasTextContent": "Zuclopenthixol   is predicted to   decrease   the effects of   rotigotine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "260",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotigotine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035071",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035071_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sacubitril\" outputclass=\"int-drug\">sacubitril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sacubitril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "261",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sacubitril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035072",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035072_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salbutamol\" outputclass=\"int-drug\">Salbutamol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salbutamol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "262",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salbutamol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035073",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035073_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"salmeterol\" outputclass=\"int-drug\">Salmeterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Salmeterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "263",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Salmeterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035074",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035074_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sapropterin\" outputclass=\"int-drug\">sapropterin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sapropterin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "264",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sapropterin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035075",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035075_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  selegiline  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "265",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035076",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035076_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"selpercatinib\" outputclass=\"int-drug\">selpercatinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  selpercatinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "266",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selpercatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035077",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035077_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sevoflurane  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035077_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  sevoflurane  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035077_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sevoflurane\" outputclass=\"int-drug\">sevoflurane</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  sevoflurane  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "267",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sevoflurane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035078",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035078_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sildenafil  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035078_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sildenafil\" outputclass=\"int-drug\">sildenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  sildenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "268",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sildenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035079",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035079_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"siponimod\" outputclass=\"int-drug\">Siponimod</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of QT-prolongation when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Siponimod   might   increase   the risk of QT-prolongation when given with   zuclopenthixol .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "269",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Siponimod</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035080",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035080_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sodium oxybate  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035080_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sodium oxybate\" outputclass=\"int-drug\">sodium oxybate</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  sodium oxybate  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "270",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium oxybate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035081",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035081_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sorafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "271",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035082",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035082_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sotalol  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035082_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sotalol\" outputclass=\"int-drug\">sotalol</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  sotalol  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "272",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sotalol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035083",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035083_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  spironolactone  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "273",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035084",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035084_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sulpiride  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035084_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  sulpiride  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035084_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sulpiride\" outputclass=\"int-drug\">sulpiride</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  sulpiride  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "274",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulpiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035085",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035085_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  sunitinib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "275",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035086",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035086_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tadalafil\" outputclass=\"int-drug\">tadalafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tadalafil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "276",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tadalafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035087",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035087_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tamsulosin\" outputclass=\"int-drug\">tamsulosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tamsulosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "277",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamsulosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035088",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035088_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tapentadol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "278",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035089",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035089_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  telmisartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "279",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035090",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035090_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"temazepam\" outputclass=\"int-drug\">temazepam</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  temazepam  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "280",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temazepam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035091",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035091_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"terazosin\" outputclass=\"int-drug\">terazosin</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  terazosin  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "281",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terazosin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035092",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035092_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"terbutaline\" outputclass=\"int-drug\">Terbutaline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Terbutaline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "282",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Terbutaline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035093",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035093_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tetrabenazine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035093_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tetrabenazine\" outputclass=\"int-drug\">tetrabenazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  tetrabenazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "283",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetrabenazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035094",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035094_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tetracaine\" outputclass=\"int-drug\">tetracaine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tetracaine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "284",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tetracaine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035095",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035095_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  thalidomide  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "285",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035096",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035096_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"theophylline\" outputclass=\"int-drug\">Theophylline</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Theophylline   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "286",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Theophylline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035097",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035097_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  thiopental  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035097_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"thiopental\" outputclass=\"int-drug\">thiopental</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  thiopental  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "287",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thiopental</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035098",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035098_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"timolol\" outputclass=\"int-drug\">timolol</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  timolol  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "288",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Timolol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035099",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035099_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tizanidine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035099_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  tizanidine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035099_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tizanidine\" outputclass=\"int-drug\">tizanidine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  zuclopenthixol  and  tizanidine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "289",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tizanidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035100",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035100_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tolterodine\" outputclass=\"int-drug\">tolterodine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tolterodine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "290",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolterodine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035101",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035101_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  torasemide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035101_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"torasemide\" outputclass=\"int-drug\">Torasemide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Torasemide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "291",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035102",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035102_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  toremifene  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "292",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035103",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035103_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tramadol  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "293",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035104",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035104_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  trandolapril  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "294",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035105",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035105_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  tranylcypromine  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "295",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035106",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035106_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  trazodone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "296",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035107",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035107_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  treprostinil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "297",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035108",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035108_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">Triamcinolone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Triamcinolone   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "298",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035109",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035109_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  trifluoperazine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035109_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"trifluoperazine\" outputclass=\"int-drug\">trifluoperazine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  trifluoperazine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "299",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trifluoperazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035110",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035110_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  trimipramine  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035110_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  trimipramine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "300",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035111",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035111_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  valsartan  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "301",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035112",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035112_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vandetanib\" outputclass=\"int-drug\">vandetanib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  vandetanib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "302",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vandetanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035113",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035113_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  vardenafil  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035113_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vardenafil\" outputclass=\"int-drug\">vardenafil</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  vardenafil  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "303",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vardenafil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035114",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035114_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vemurafenib\" outputclass=\"int-drug\">vemurafenib</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  vemurafenib  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "304",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vemurafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035115",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035115_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  venlafaxine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035115_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  venlafaxine  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "305",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035116",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035116_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"verapamil\" outputclass=\"int-drug\">verapamil</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  verapamil  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "306",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Verapamil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035117",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035117_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vericiguat\" outputclass=\"int-drug\">vericiguat</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  vericiguat  can increase the risk of hypotension. \n\n"
						}
					],
					"hasOrder": "307",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vericiguat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035118",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035118_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vernakalant\" outputclass=\"int-drug\">vernakalant</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  vernakalant  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035118_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vernakalant\" outputclass=\"int-drug\">vernakalant</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  zuclopenthixol  and  vernakalant  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "308",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vernakalant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035119",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035119_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"vilanterol\" outputclass=\"int-drug\">Vilanterol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Vilanterol   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "309",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vilanterol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035120",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035120_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  vinflunine  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "310",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035121",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035121_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">voriconazole</ph> prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  voriconazole  prolong the QT interval. Most manufacturers advise avoiding the use of two or more drugs that are associated with QT prolongation. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation.  \n\n"
						}
					],
					"hasOrder": "311",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035122",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035122_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hypotension.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  xipamide  can increase the risk of hypotension. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035122_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"xipamide\" outputclass=\"int-drug\">Xipamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">cause</ph> <ph outputclass=\"int-parameter\">hypokalaemia (potentially increasing the risk of torsade de pointes) when given with</ph> <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Xipamide   is predicted to   cause   hypokalaemia (potentially increasing the risk of torsade de pointes) when given with   zuclopenthixol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "312",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035123",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035123_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"zolpidem\" outputclass=\"int-drug\">zolpidem</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  zolpidem  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "313",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolpidem</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035124",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2#bnf_i1643858035124_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"zuclopenthixol\" outputclass=\"int-heading-drug\">zuclopenthixol</ph> and <ph otherprops=\"zopiclone\" outputclass=\"int-drug\">zopiclone</ph> can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in <xref format=\"dita\" href=\"guidance/guidance-on-prescribing.xml\" type=\"interaction\" rel=\"guidance\" bnfid=\"PHP97234\">Guidance on Prescribing</xref>).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  zuclopenthixol  and  zopiclone  can have CNS depressant effects, which might affect the ability to perform skilled tasks (see 'Drugs and Driving' in  Guidance on Prescribing ). \n\n"
						}
					],
					"hasOrder": "314",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zopiclone</title>"
					}
				}
			],
			"hasSearchLabel": " Zuclopenthixol  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/zuclopenthixol-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Zuclopenthixol </title>"
			},
			"rdfs:label": "zuclopenthixol"
		}
	]
}